This article is more than 5 years old. Information may no longer be current.

Jetrea now available in Denmark and Sweden

Issue: July/August 2013

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ThromboGenics announced that its partner, Alcon, has launched Jetrea to treat adults with vitreomacular traction in both Denmark and Sweden.

“We are extremely encouraged by our partner, Alcon’s, rapid progress in making Jetrea (ocriplasmin) available across Europe. We look forward to further launches across the Nordic region and other countries to ensure that patients are able to have access to the first pharmacological treatment for VMT, including when associated with macular hole of diameter less than or equal to 400 µm,” Patrik De Haes, MD, CEO of ThromboGenics, said in a press release.

ThromboGenics and Alcon are continuing to develop the infrastructure necessary to provide patients across Europe and beyond with Jetrea as soon as it becomes available in other countries.